作者
N Vasdev, H Zargar, JP Noël, R Veeratterapillay, AS Fairey, LS Mertens, CP Dinney, MC Mir, LM Krabbe, MS Cookson, NE Jacobsen, NM Gandhi, J Griffin, JS Montgomery, EY Yu, E Xylinas, NJ Campain, W Kassouf, MA Dall’Era, JA Seah, CE Ercole, S Horenblas, SS Sridhar, JS McGrath, J Aning, SF Shariat, JL Wright, TM Morgan, TJ Bivalacqua, S North, DA Barocas, Yair Lotan, P Grivas, AJ Stephenson, Jay Bakul Shah, BW van Rhijn, S Daneshmand, PE Spiess, JM Holzbeierlein, A Thorpe, PC Black
发表日期
2019/1/23
期刊
World journal of urology
卷号
37
页码范围
165-172
出版商
Springer Berlin Heidelberg
简介
Background
Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the detection of carcinoma in situ (CIS) at the time of initial transurethral resection of bladder tumor (TURBT) has an oncological impact on the response to NAC prior to radical cystectomy.
Patients and methods
Patients were identified retrospectively from 19 centers who received at least three cycles of NAC or induction chemotherapy for cT2-T4aN0-3M0 urothelial carcinoma of the bladder followed by radical cystectomy between 2000 and 2013. The primary and secondary outcomes were pathological response and overall survival, respectively. Multivariable analysis was performed to determine the independent predictive value of CIS on these outcomes …
学术搜索中的文章
N Vasdev, H Zargar, JP Noël, R Veeratterapillay… - World journal of urology, 2019